NCT04798781

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Andrew Hendifar, MD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of telatinib in combination with Keytruda on progression-free survival.

Conditions

• Gastric Cancer
• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Telatinib	900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent
DRUG	Keytruda	200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent

Timeline

• Start date: 2021-07-28
• Primary completion: 2024-02-14
• Completion: 2025-10-20
• First posted: 2021-03-15
• Last updated: 2025-12-11
• Results posted: 2024-10-10

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study